Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 13 of 14

2. Compass Therapeutics Inc (NASDAQ:CMPX)

Number of Hedge Fund Holders In Q4 2024: 14

Compass Therapeutics Inc (NASDAQ:CMPX) is a biopharmaceutical company that makes antibody-based therapies for several diseases.

The stock is up significantly so far in 2025 due to it reporting 2024 results and its anticipated top-line Phase 2/3 data readout for COMPANION-002, which is evaluating tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC). It is expected by the end of the first quarter of 2025.

In addition, Compass Therapeutics announced in January 2025 that it is advancing a new drug candidate, CTX-10726, a PD-1 x VEGF-A bispecific antibody, with IND submission expected by the end of 2025.

The consensus price target of $11.38 implies 289.55% upside.

CMPX is up 101.38% year-to-date.

Page 13 of 14